GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Haisco Pharmaceutical Group Co Ltd (SZSE:002653) » Definitions » Net Income Including Noncontrolling Interests

Haisco Pharmaceutical Group Co (SZSE:002653) Net Income Including Noncontrolling Interests : ¥358 Mil (TTM As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Haisco Pharmaceutical Group Co Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Haisco Pharmaceutical Group Co's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2024 was ¥91 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 was ¥358 Mil.


Haisco Pharmaceutical Group Co Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Haisco Pharmaceutical Group Co's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haisco Pharmaceutical Group Co Net Income Including Noncontrolling Interests Chart

Haisco Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only 474.85 601.20 517.58 391.72 295.56

Haisco Pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.40 43.25 129.55 94.37 90.72

Haisco Pharmaceutical Group Co Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥358 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Haisco Pharmaceutical Group Co Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Haisco Pharmaceutical Group Co's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.


Haisco Pharmaceutical Group Co (SZSE:002653) Business Description

Industry
Traded in Other Exchanges
N/A
Address
No. 17, Sanxiang Avenue, Shannan District, Tibet Autonomous Region, Zetang, CHN, 856000
Haisco Pharmaceutical Group Co Ltd is a pharmaceutical company based in China. It is mainly engaged in the research, development, manufacture, and sale of drugs for liver disease. Its product portfolio includes parenteral nutrition drugs, antibiotics, anesthetic agents, digestive system drugs and tumour adjuvant drug series. The company's products are being used in first rank hospitals in China.
Executives
Fan Xiu Lian Directors, executives
Zheng Wei Directors, executives
Wang Meng Secretary Dong
Wang Jun Min Directors, executives
Deng Xiang Directors, executives
Liu Han Bing Supervisors
Zhang Xiao Xu Supervisors
Tan Hong Executives
Shen Ping Director
Liang Yong Supervisors
Chen Long Independent director
Duan Qing Liang Supervisors

Haisco Pharmaceutical Group Co (SZSE:002653) Headlines

No Headlines